About Glaukos
Glaukos is a company based in Laguna Hills (United States) founded in 2001. Glaukos has raised $117.57 million across 10 funding rounds from investors including Orbimed, Frazier Healthcare Partners and Meritech Capital. The company has 995 employees as of December 31, 2024. Glaukos has completed 1 acquisition, including Avedro. Glaukos operates in a competitive market with competitors including Ivantis, Myra Vision, Transcend Medical, InnFocus and AqueSys, among others.
- Headquarter Laguna Hills, United States
- Employees 995 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Glaukos Corporation
-
Annual Revenue
$383.48 M (USD)21.85as on Dec 31, 2024
-
Net Profit
-$146.37 M (USD)-8.7as on Dec 31, 2024
-
EBITDA
-$68.22 M (USD)20.42as on Dec 31, 2024
-
Total Equity Funding
$117.57 M (USD)
in 10 rounds
-
Latest Funding Round
$250 M (USD), Post-IPO
Jun 08, 2020
-
Investors
Orbimed
& 7 more
-
Employee Count
995
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Glaukos
Glaukos is a publicly listed company on the NYSE with ticker symbol GKOS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Glaukos
Unlock access to complete
Unlock access to complete
Funding Insights of Glaukos
Glaukos has successfully raised a total of $117.57M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $250 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Glaukos
Glaukos has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Frazier Healthcare Partners and Meritech Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward US-based companies.
|
Locked | Locked | Locked | |
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked |
Investor details for Glaukos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Glaukos
Glaukos has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Avedro.
Investment portfolio details for Glaukos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Corneal collagen cross-linking technology is developed for ophthalmic applications.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Glaukos
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Glaukos
Detailed financials for Glaukos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glaukos Comparisons
Peer comparison for Glaukos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Glaukos
Glaukos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ivantis, Myra Vision, Transcend Medical, InnFocus and AqueSys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Implantable device to relieve intraocular pressure in open angle glaucoma
|
|
| Locked | Locked | Locked |
Nanotechnology-based devices for glaucoma treatment are developed.
|
|
| Locked | Locked | Locked |
Minimally invasive glaucoma stents are developed to enhance aqueous outflow.
|
|
| Locked | Locked | Locked |
Glaucoma is treated via the implantable MicroShunt device in ophthalmology.
|
|
| Locked | Locked | Locked |
Implantable devices for glaucoma treatment are developed by AqueSys.
|
Detailed competitors of Glaukos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glaukos
Complete news archive for Glaukos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glaukos
Glaukos was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Glaukos is headquartered in Laguna Hills, United States. It is registered at Laguna Hills, California, United States.
Glaukos is a funded company, having raised a total of $117.57M across 10 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Glaukos is 995.
Annual revenue of Glaukos is $383.48M as on Dec 31, 2024.
The company was founded in 2001 and is headquartered in Laguna Hills, United States, within the medical devices sector focused on ophthalmology. Operations center on the development of the Micro-Invasive Glaucoma Surgery (MIGS) method, including the iStent device, which is implanted during cataract surgery to reduce intraocular pressure. Additional platforms for bioerodible drug delivery targeting retinal disorders are also being advanced.
Glaukos's top competitors include Myra Vision, Avisi Technologies and Sanoculis.
Yes, Glaukos is publicly traded on NYSE under the ticker symbol GKOS.
Glaukos has made 1 acquisition, including Avedro.
Glaukos has 8 investors. Key investors include Orbimed, Frazier Healthcare Partners, Meritech Capital, Domain Associates, and InterWest.
The ticker symbol of Glaukos is GKOS on NYSE.